Lilly says donanemab slowed cognitive, functional decline in AD patients in Phase 3 study
In the trial, donanemab lowered the risk of disease progression and half of the participants who were at…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Jul 23
In the trial, donanemab lowered the risk of disease progression and half of the participants who were at…
18 Jul 23
These recommendations, which have been developed through the Executive Steering Group on Shortages and Safety of Medicinal Products…
18 Jul 23
Healthcare-associated infections (HAI), also known as hospital-acquired infections, are a major problem healthcare systems face worldwide. Each year,…
18 Jul 23
The disinterested members of the Pardes Board of Directors have unanimously determined that the acquisition by Purchaser is…
17 Jul 23
The approval was based on findings from a Phase 1 study, as well as results from the Phase…
17 Jul 23
Xpovio is said to be the first authorised selective inhibitor of the XPO1 in the world that promotes…
17 Jul 23
In the trial, ACU193 met the primary and secondary objectives in both single and multiple doses in 60…
17 Jul 23
GHz-Class NMR, Structural Biology assisted by Artificial Intelligence, a New Scientific Software Division and Innovative Helium Solutions at…
17 Jul 23
Deenova, the undisputed leading supplier of innovative pharmacy automation solutions for healthcare facilities, is delighted to announce the…
17 Jul 23
Gustave Roussy and THERYQ announce a strategic and structuring partnership to roll out and assess FLASH technology for…